US.CRL · Charles River Laboratories

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.106081474559539,
        "turnoverUsdM": 227.57894628962998,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 264.1722,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.2,
      "take_profit_price": 298.57,
      "target_multiplier": 1.9,
      "technical_strength": 1.53,
      "take_profit_percent": 6
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.212162949119078,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 57.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 46.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 286.075,
    "ma50": 262.6152,
    "close": 281.67,
    "prevClose": 273.41,
    "avgVolume20": 871718,
    "volumeRatio": 0.93,
    "changePercent": 3.02
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": 0.03175827838827838,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 0.9174204317069571,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 1.3306988308496819,
      "volat_points": 2,
      "day_range_pct": 0.03949657260281277,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 57.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 5.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 26,
        "contribution": 5.2
      },
      {
        "raw": 9.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 62.67,
        "contribution": 9.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 18.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 63,
        "contribution": 18.9
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 46.3,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 5.2/20分",
      "市場環境分析總分: 9.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 18.9/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.5,
      "資金流": 5.2,
      "市場環境": 9.4,
      "情緒分析": 3,
      "技術信號": 18.9,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 227.57894628962998,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 17.71
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 712.7094935,
                "ma50": 709.9877978999997,
                "name": "QQQ",
                "close": 716.91998,
                "points": 2
              },
              "spy": {
                "ma20": 764.3489924499997,
                "ma50": 759.53139858,
                "name": "SPY",
                "close": 762.59998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.106081474559539,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142197359,
                "url": "https://finnhub.io/api/news?id=60489fd50614fe61d828e50cb5471c4bf5938520da3eae9ad24994eeeff76955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789571812,
                "headline": "3 Reasons to Sell CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 142164697,
                "url": "https://finnhub.io/api/news?id=f87e70418d4cccf16f505216a16eb0b4c07db5295f76c722453ec95062ef86f0",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) 2026 Global Healthcare Conference September 15, 2026 9:40 AM EDTCompany ParticipantsGlenn Coleman -...",
                "category": "company",
                "datetime": 1789475497,
                "headline": "Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142138791,
                "url": "https://finnhub.io/api/news?id=397c4265b81776cbba9ecfaa38fa6602b07b77abb57ab57d1c789e2ca3659317",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany...",
                "category": "company",
                "datetime": 1789389099,
                "headline": "Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 141437887,
                "url": "https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141370262,
                "url": "https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.",
                "category": "company",
                "datetime": 1788276600,
                "headline": "Is This the Right Time to Add CRL Stock to Your Portfolio?"
              },
              {
                "id": 141336294,
                "url": "https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1787909718,
                "headline": "Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"
              },
              {
                "id": 141285572,
                "url": "https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...",
                "category": "company",
                "datetime": 1787382551,
                "headline": "Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"
              },
              {
                "id": 141285581,
                "url": "https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...",
                "category": "company",
                "datetime": 1787357537,
                "headline": "Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"
              }
            ],
            "raw_source": [
              {
                "id": 142224593,
                "url": "https://finnhub.io/api/news?id=6ad8f53023808dd818c5fb4e0dbf3bf7ef3c55ee984a482592b617ca1a740d83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 17, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehens",
                "category": "company",
                "datetime": 1789646400,
                "headline": "Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines"
              },
              {
                "id": 142197359,
                "url": "https://finnhub.io/api/news?id=60489fd50614fe61d828e50cb5471c4bf5938520da3eae9ad24994eeeff76955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789571812,
                "headline": "3 Reasons to Sell CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 142194922,
                "url": "https://finnhub.io/api/news?id=f9048c5d7a8775f334716a76a048fe2c1d0299955bd17423804eb6419dd2b1f0",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.57% on an annualized basis producing an average annual return of 15.86%. Currently, Charles River has a market capitalization of $13.95",
                "category": "company",
                "datetime": 1789493525,
                "headline": "Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 142164697,
                "url": "https://finnhub.io/api/news?id=f87e70418d4cccf16f505216a16eb0b4c07db5295f76c722453ec95062ef86f0",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) 2026 Global Healthcare Conference September 15, 2026 9:40 AM EDTCompany ParticipantsGlenn Coleman -...",
                "category": "company",
                "datetime": 1789475497,
                "headline": "Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142138791,
                "url": "https://finnhub.io/api/news?id=397c4265b81776cbba9ecfaa38fa6602b07b77abb57ab57d1c789e2ca3659317",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany...",
                "category": "company",
                "datetime": 1789389099,
                "headline": "Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142137074,
                "url": "https://finnhub.io/api/news?id=ed61199d8e769d6ae13564b8886127c0d035534ea2808856e63e0e001fe7722c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "FIGS, APH and MSFT post strong gains as Zacks upgrades and model portfolios spotlight stocks outperforming the broader market.",
                "category": "company",
                "datetime": 1789387860,
                "headline": "Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus"
              },
              {
                "id": 142084682,
                "url": "https://finnhub.io/api/news?id=6ef799272bb862265c32e71a2510258b2a007c8e9d8289de2feea83698d663a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1789134002,
                "headline": "Are Medical Stocks Lagging  Amgen (AMGN) This Year?"
              },
              {
                "id": 142080461,
                "url": "https://finnhub.io/api/news?id=3cba58b7a38a0d0ac5cb9d20d30ee129c242160688a84c9d2101067566358306",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 11, 2026--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences",
                "category": "company",
                "datetime": 1789128000,
                "headline": "Charles River Laboratories to Present at Morgan Stanley and Baird Conferences"
              },
              {
                "id": 142091518,
                "url": "https://finnhub.io/api/news?id=e5b70d2ca4fc83e9521085cc99f6fcc54c29dae0cb4abe6829850b59a487c765",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.",
                "category": "company",
                "datetime": 1789126295,
                "headline": "Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320"
              },
              {
                "id": 141951308,
                "url": "https://finnhub.io/api/news?id=c3eedd324610a4d2372d995fee82bd5c98d436e6c2ab5b0c58af6ad0bfd79f9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 08, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity.",
                "category": "company",
                "datetime": 1788868800,
                "headline": "Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite"
              },
              {
                "id": 141913510,
                "url": "https://finnhub.io/api/news?id=93030636154aeb4442631985be95aeeb84233bfcad77a6092698cf29fcc0784c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238217382/image_2238217382.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.",
                "category": "company",
                "datetime": 1788848276,
                "headline": "Health Care's Next Act: Tailwinds Emerging Across R&D Cycle"
              },
              {
                "id": 141437887,
                "url": "https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141370261,
                "url": "https://finnhub.io/api/news?id=dccb73f21d41e94b3ecd3b16b380aa2067c9f976406280e57a6c3ae7664bd5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.",
                "category": "company",
                "datetime": 1788278340,
                "headline": "Here's Why You Should Hold Charles River Stock in Your Portfolio Now"
              },
              {
                "id": 141370262,
                "url": "https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.",
                "category": "company",
                "datetime": 1788276600,
                "headline": "Is This the Right Time to Add CRL Stock to Your Portfolio?"
              },
              {
                "id": 141336294,
                "url": "https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1787909718,
                "headline": "Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"
              },
              {
                "id": 141365553,
                "url": "https://finnhub.io/api/news?id=fdc5dcdc431b9ef146e761d842d30c65873936be48b831238710ef6a9c07f771",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035\" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro",
                "category": "company",
                "datetime": 1787831520,
                "headline": "Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific"
              },
              {
                "id": 141365554,
                "url": "https://finnhub.io/api/news?id=9b4143fb26738fb4ce760aa104946f153b883c1808ce5fea5f547950c7d60d69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.",
                "category": "company",
                "datetime": 1787751811,
                "headline": "Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?"
              },
              {
                "id": 141324273,
                "url": "https://finnhub.io/api/news?id=03721ff268f5dbbeade78dfd1e473153bf81c7da1a58b90d820bc733d942d886",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22",
                "category": "company",
                "datetime": 1787675434,
                "headline": "Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 141365555,
                "url": "https://finnhub.io/api/news?id=bb316e03900c98af836f471c4cf8f628d54928ccd4e2251213ea8fb7f392281b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1787668803,
                "headline": "Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 141363104,
                "url": "https://finnhub.io/api/news?id=6f5f1c3e39904371e861a27af556e7dccd9d7f4859716741bd9eb776c40e458f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
                "category": "company",
                "datetime": 1787660324,
                "headline": "3 Inflated  Stocks We Approach with Caution"
              },
              {
                "id": 141313731,
                "url": "https://finnhub.io/api/news?id=515bc7cdf58d72a1174672bd595355a9f13d453d64545924216c27831956087e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Ariel Investments' 13F portfolio rose to $10.03B in Q2 2026, with 27 core positions, each over 2% of assets. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787608034,
                "headline": "Tracking John Rogers' Ariel Investments Portfolio - Q2 2026 Update"
              },
              {
                "id": 141285572,
                "url": "https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...",
                "category": "company",
                "datetime": 1787382551,
                "headline": "Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"
              },
              {
                "id": 141285581,
                "url": "https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...",
                "category": "company",
                "datetime": 1787357537,
                "headline": "Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"
              },
              {
                "id": 141282338,
                "url": "https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.",
                "category": "company",
                "datetime": 1787326620,
                "headline": "CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"
              },
              {
                "id": 141285574,
                "url": "https://finnhub.io/api/news?id=d55e1da5409b429b35a7e8668915c0b4b965ccb81c477b45942733fffe190b30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Investors need to pay close attention to CRL stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1787326140,
                "headline": "Are Options Traders Betting on a Big Move in Charles River Stock?"
              },
              {
                "id": 141285575,
                "url": "https://finnhub.io/api/news?id=1e12ffa39729ca80a074f28e25ebc90e0f13ac69e39100a037ee9c241e4da6e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.",
                "category": "company",
                "datetime": 1787323800,
                "headline": "Charles River Gains 88.6% in a Year: What's Driving the Rally?"
              },
              {
                "id": 141285576,
                "url": "https://finnhub.io/api/news?id=b2b5eccf3c195c8eeeeab121ada79465da1aee4e17871e56b32bb091bbe98e1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent",
                "category": "company",
                "datetime": 1787230800,
                "headline": "Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing"
              },
              {
                "id": 141262451,
                "url": "https://finnhub.io/api/news?id=a978100f9c3dbfb785d08bbc780cce434527e9bc36bd7a900f59c0d83731d12b",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and",
                "category": "company",
                "datetime": 1787213070,
                "headline": "Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine"
              },
              {
                "id": 141278737,
                "url": "https://finnhub.io/api/news?id=67621dd00d7b4422294b7c05c38a9ef3f25ba0e393e2e079e5179b2aacf01c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The \"Protein Design and Engineering Market Global Report 2026\" has been added to ResearchAndMarkets.com's o",
                "category": "company",
                "datetime": 1787153280,
                "headline": "Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 29,
            "discarded_article_count": 20
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.9,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 3,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(18.2%→10.1%)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 935126.6666666666,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 842590,
              "avg_vol_20": 880690,
              "avg_vol_30": 935126.6666666666,
              "range_pct_10": 0.10118223093754283,
              "range_pct_20": 0.12795117946706502,
              "range_pct_30": 0.18191497561277467,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9010437088736643,
              "dist_to_20d_high": 0.07134611453628305,
              "down_shrink_days": 4,
              "breakout_level_20d": 303.31,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.556206164977423
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.106081474559539,
              "turnoverUsdM": 227.57894628962998,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 264.1722,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.2,
            "take_profit_price": 298.57,
            "target_multiplier": 1.9,
            "technical_strength": 1.53,
            "take_profit_percent": 6
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.212162949119078,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 8.7489,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.11
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -48.85
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0362
    },
    "kdj": {
      "d": 25.92,
      "j": 48.22,
      "k": 33.35,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 32.99
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 5980463,
      "recentSlope": -280033.7,
      "previousSlope": -73860
    },
    "rsi": 38.64,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 10,
      "trend": "上升",
      "value": 267.27,
      "position": "SAR由上轉下+趨勢強",
      "distancePct": 5.11,
      "previousTrend": "下降"
    },
    "ma50": 262.6152,
    "macd": {
      "macd": 2.445882538593821,
      "trend": "中性偏多",
      "signal": 5.654495760869252,
      "histogram": -3.2086132222754307
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 285.7531,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.93,
      "score": 4,
      "avgVolume": 871718,
      "currentVolume": 807963
    },
    "derived": {
      "ma20": 286.075,
      "ma50": 262.6152,
      "prevClose": 273.41,
      "avgVolume10": 862736,
      "avgVolume20": 871718,
      "changePercent": 3.02,
      "avgVolumeForScore": 871718
    },
    "ma_cross": {
      "ma20": 286.075,
      "ma50": 262.6152,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 286.4915,
      "prevMa50": 261.461,
      "spreadPct": 8.93,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 268.3464,
      "upper": 303.8036,
      "position": "中間"
    },
    "rsi_short": 56.7,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.93
    }
  }
}

{
  "close": 281.67,
  "volume": 807963,
  "changePercent": 3.02
}